SEC Form 4 · accession 0001237899-16-000085
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles A Baker
Director
Period of report
Dec 12, 2016
Accepted (ET)
Dec 14, 2016 · 5:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 12, 2016 | M | 3,000 | $18.61 | A | 12,000 | D | |
| Common StockF2 | Dec 12, 2016 | S | 600 | $390.67 | D | 11,400 | D | |
| Common StockF3 | Dec 12, 2016 | S | 1,200 | $391.36 | D | 10,200 | D | |
| Common StockF4 | Dec 12, 2016 | S | 400 | $392.41 | D | 9,800 | D | |
| Common StockF5 | Dec 12, 2016 | S | 600 | $393.64 | D | 9,200 | D | |
| Common StockF6 | Dec 12, 2016 | S | 200 | $394.33 | D | 9,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F7 | $18.61 | Dec 12, 2016 | M | 3,000 | D | — | Jan 2, 2019 | Common Stock | 3,000 | 2,000 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2Represents volume-weighted average price of sales of 600 shares of Company stock on December 12, 2016 at prices ranging from $390.26 to $390.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price.
- F3Represents volume-weighted average price of sales of 1,200 shares of Company stock on December 12, 2016 at prices ranging from $391.02 to $391.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price.
- F4Represents volume-weighted average price of sales of 400 shares of Company stock on December 12, 2016 at prices ranging from $392.00 to $392.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price.
- F5Represents volume-weighted average price of sales of 600 shares of Company stock on December 12, 2016 at prices ranging from $393.39 to $393.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price.
- F6Represents volume-weighted average price of sales of 200 shares of Company stock on December 12, 2016 at prices ranging from $394.24 to $ 394.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price.
- F7The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.